Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SERRETTA, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.741
EU - Europa 8.205
AS - Asia 5.843
SA - Sud America 1.099
AF - Africa 166
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 11
Totale 30.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.583
SG - Singapore 2.222
CN - Cina 1.998
IT - Italia 1.874
RU - Federazione Russa 1.174
FI - Finlandia 1.076
UA - Ucraina 988
BR - Brasile 949
DE - Germania 785
HK - Hong Kong 634
IE - Irlanda 570
GB - Regno Unito 436
SE - Svezia 371
PL - Polonia 308
VN - Vietnam 268
FR - Francia 202
IN - India 151
KR - Corea 99
BE - Belgio 97
RO - Romania 94
CA - Canada 79
CI - Costa d'Avorio 66
JP - Giappone 63
BD - Bangladesh 59
AR - Argentina 56
AT - Austria 52
MX - Messico 49
TR - Turchia 48
CH - Svizzera 36
IQ - Iraq 36
NL - Olanda 36
UZ - Uzbekistan 34
ZA - Sudafrica 33
ID - Indonesia 25
AU - Australia 22
CZ - Repubblica Ceca 22
CO - Colombia 21
MY - Malesia 21
ES - Italia 20
EC - Ecuador 18
VE - Venezuela 17
IR - Iran 16
PH - Filippine 16
PK - Pakistan 16
SA - Arabia Saudita 16
IL - Israele 15
EG - Egitto 14
MA - Marocco 14
CL - Cile 13
GR - Grecia 12
JO - Giordania 12
AZ - Azerbaigian 11
LT - Lituania 11
AE - Emirati Arabi Uniti 9
LB - Libano 9
PY - Paraguay 9
TN - Tunisia 9
KZ - Kazakistan 8
NP - Nepal 8
UY - Uruguay 8
AL - Albania 7
OM - Oman 7
DZ - Algeria 6
EU - Europa 6
GE - Georgia 6
KW - Kuwait 6
BH - Bahrain 5
HN - Honduras 5
JM - Giamaica 5
KE - Kenya 5
NZ - Nuova Zelanda 5
PE - Perù 5
RS - Serbia 5
TW - Taiwan 5
AM - Armenia 4
AO - Angola 4
BB - Barbados 4
BG - Bulgaria 4
MD - Moldavia 4
PT - Portogallo 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
CM - Camerun 3
KH - Cambogia 3
PA - Panama 3
SD - Sudan 3
SN - Senegal 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
ET - Etiopia 2
LU - Lussemburgo 2
ME - Montenegro 2
MM - Myanmar 2
MN - Mongolia 2
NG - Nigeria 2
SI - Slovenia 2
SV - El Salvador 2
Totale 30.069
Salva come PNG Salva come JPEG
Città #
Ashburn 1.926
Fairfield 1.631
Singapore 1.250
Chandler 1.084
Woodbridge 867
Wilmington 822
Ann Arbor 759
Houston 690
Seattle 629
Hong Kong 615
Dublin 568
Jacksonville 526
Cambridge 515
Medford 413
Beijing 379
Nanjing 275
Des Moines 268
Princeton 265
Zgierz 259
Moscow 225
Palermo 180
New York 172
Altamura 171
Los Angeles 166
The Dalles 163
Hefei 157
Boardman 150
Dallas 148
Tulsa 148
Lawrence 137
Dearborn 122
Helsinki 111
Nanchang 108
Buffalo 107
San Diego 106
Ho Chi Minh City 97
Brussels 96
Milan 94
Shenyang 92
São Paulo 84
Santa Clara 78
Hebei 73
Changsha 70
Council Bluffs 69
Abidjan 66
Tianjin 64
Jiaxing 62
Hanoi 61
Ludwigshafen am Rhein 61
Columbus 52
Munich 52
Nuremberg 50
London 49
Tokyo 48
Seongnam 46
Jinan 45
Guangzhou 43
Kumar 43
Saint Petersburg 43
Rome 40
Verona 40
Zhengzhou 38
Redwood City 37
Bremen 34
Venice 34
Nave 33
Denver 31
Auburn Hills 30
Chicago 30
Seoul 29
Frankfurt am Main 27
Rio de Janeiro 27
Toronto 27
Falls Church 26
Montreal 26
Ningbo 26
San Mateo 26
Tashkent 26
Warsaw 26
Belo Horizonte 25
San Paolo di Civitate 25
Washington 22
Turku 21
Chennai 20
Düsseldorf 20
Boston 19
Johannesburg 19
Lanzhou 19
Phoenix 19
Falkenstein 18
Hangzhou 18
Kunming 18
Taizhou 18
Vienna 18
Baghdad 17
Napoli 17
Stockholm 17
Curitiba 16
Norwalk 16
Brooklyn 15
Totale 18.660
Salva come PNG Salva come JPEG
Nome #
S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy? 543
Characterization of human infiltrating and circulating gamma-delta t cells in prostate cancer 261
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 250
Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice 238
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder. 231
Manuale di Urologia e Andrologia. Capitolo 1: Anatomia dell'apparato genito-urinario 226
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 225
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 217
Cytokine gene expression in the tunica albuginea 
of patients with Peyronie’s disease. Pilot study with 
a control group 210
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. 209
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma 204
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors 199
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 197
Cytokines gene expression in the tunica albuginea of patients with Peyronie’s disease. Pilot study with a control group 190
Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study 187
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica. 180
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder 179
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 178
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? 173
Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 173
Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case 172
Carcinoma uroteliale in cisti pielogena 171
Il carcinoma prostatico in Calabria e Sicilia. 170
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 170
The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the epidermal growth factor receptor and fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer 167
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions 165
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients 165
Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group 159
Mitomycin C from birth to adulthood 159
Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment. 158
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 158
Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva 156
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. 156
Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked! 155
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder 155
WHATSAPP MESSENGER AS A REAL-TIME TOOL FOR A LONG-DISTANCE ACTIVITY OF A MULTIDISCIPLINARY 153
TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI 152
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer 151
Genitourinary Symptoms-Patient Help-Seeking and General Practitioner Management: An Outpatient Based Survey at a Tertiary Hospital in Southern Italy 151
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor 150
Correlation between chronic prostatitis syndrome and pelvic venous disease. A survey of 2554 urologic outpatients 150
Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression 150
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 150
Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy? 149
INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY 148
Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study 148
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 148
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 147
Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study 147
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE? 146
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 146
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 145
Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica 145
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer 145
Management of bicalutamide induced gynaecomastia. A randomized study comparing therapy versus prophylaxis with tamoxifen. 144
T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! 144
Correlation between BMI and the pathological features of prostate cancer at biopsy 144
Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma 143
Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical toxicity of adjuvant intravesical therapy for non muscle invasive bladder cancer (NMI-BC) 142
Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis 142
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studio Tumori Urologici (GSTU). 140
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studi Tumori Urologici (GSTU) 140
PSA and second-line therapy of hormone refractory prostate carcinoma 140
PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA) 139
Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale 138
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study 138
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years 138
La terapia dei tumori vescicali superficiali: lo stato attuale 137
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione – 137
Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale. 133
La p53 nel tumore vescicale superficiale (Ta-T1, G1-3) 133
A randomized phase II study of estramustine phosphate versus estramustine phosphate plus etoposide in hormone refractory prostate cancer (HRPC). 133
PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS 133
Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562. 132
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma. 132
Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes 132
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1. 131
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 131
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer 130
PLEOMORPHIC HYALINIZING ANGIOECTATIC TUMOR (PHAT) OF RENAL PARENCHYMA. FIRST CASE REPORTED IN LITERATURE 128
The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. 128
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study 128
Can we clinically distinguish anejaculation from retrograde ejaculation in patients on α1A-blockers therapy for lower urinary tract symptoms? 128
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin 127
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study 126
Fattori di rischio ambientali nella storia naturale del carcinoma vescicale superficiale. 126
Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine 126
A RANDOMIZED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER. 126
Single dose prulifloxacina can improve BCG tollerability 126
Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Gue´ rin: Results of a retrospective Multicenter Study of 2451 Patients 126
Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital 126
Studio randomizzato multicentrico: mantenimento mensile per un anno versus induzione per 6 settimane nella chemioprofilasi precoce dopo TUR. 125
Compliance to therapy with Dapoxetine in comparison to a conventional selective serotonin reuptake inhibitor (Citalopram) in 118 patients with premature ejaculation. 125
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought 125
Environmental factors in superficial bladder cancer. Preliminary report of a prospective study 124
Environmental factors in superficial bladder cancer. Preliminary report of a prospective study 124
Clinical pitfalls in diagnosis of nonmuscle-invasive bladder cancer 124
Efficacia del mantenimento nella chemioprofilassi endovescicale precode dopo TUR. Risultati di uno studio randomizzato multicentrico. 123
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU) 123
TUR AND ADJUVANT INTRAVESCICAL CHEMOTHERAPY IN T1G3 BLADDER TUMORS. RECURRENCE, PROGRESSION AND SURVIVAL IN 137 SELECTED PATIENTS FOLLOWED UP TO 20 YEARS. 123
Totale 15.790
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.944
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.770 0 0 0 0 0 163 268 149 317 223 277 373
2021/20222.688 126 575 61 140 150 115 73 142 332 331 108 535
2022/20233.770 418 549 89 334 406 498 226 238 801 21 137 53
2023/20241.744 71 239 171 180 153 358 153 126 11 21 75 186
2024/20254.128 138 218 199 370 204 153 258 295 359 431 618 885
2025/20265.471 1.114 467 790 1.024 1.325 751 0 0 0 0 0 0
Totale 30.922